<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412017000800489</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evidencias en indicaciones de la progesterona]]></article-title>
<article-title xml:lang="en"><![CDATA[Evidence in progesterone prescription]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Buitrón-García]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bailón-Uriza]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santoyo-Haro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz-Sánchez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General de México Dr. Eduardo Liceaga Servicio de Ginecología y Obstetricia ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Médica Sur Servicio de Ginecología y Obstetricia ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Unidad Médica de Alta Especialidad en Ginecología y Obstetricia Luis Castelazo Ayala Servicio de Ginecología y Obstetricia]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,International Planned Parenthood Federation Unidad de Desarrollo Institucional ]]></institution>
<addr-line><![CDATA[Nueva York ]]></addr-line>
<country>USA</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2017</year>
</pub-date>
<volume>85</volume>
<numero>8</numero>
<fpage>489</fpage>
<lpage>497</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412017000800489&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412017000800489&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412017000800489&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  ANTECEDENTES: la progesterona es una hormona esteroide con participación en la ovulación, implantación, embarazo y regulación de la función uterina durante el ciclo menstrual y de otros órganos, como la glándula mamaria. Por su mecanismo de acción, la progesterona está indicada en distintos padecimientos ginecológicos y obstétricos: síndrome premenstrual, amenaza de aborto, parto pretérmino, hemorragia uterina disfuncional y mastalgia relacionada con el ciclo menstrual.  OBJETIVO: evaluar la seguridad y eficacia de la progesterona en pacientes con: síndrome premenstrual, amenaza de aborto y de parto pretérmino, hemorragia uterina disfuncional, mastalgia y terapia hormonal en la menopausia.  METODOLOGÍA: revisión sistemática de la evidencia científica acerca de las distintas indicaciones de la progesterona.  RESULTADOS: se encontraron 92 artículos de los que se seleccionaron 41 para revisión.  CONCLUSIONES: la evidencia clínica evaluada acerca de las indicaciones de la progesterona demuestra ventajas en eficacia y seguridad en los diferentes esquemas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  BACKGROUND: Progesterone is a steroid hormone involved in ovulation, implantation, pregnancy and regulation of uterine function during the menstrual cycle and other organs such as the mammary gland. Because of its mechanism of action, progesterone is indicated in different gynecological and obstetric conditions: premenstrual syndrome, threatened abortion, preterm birth, dysfunctional uterine bleeding and mastalgia related to the menstrual cycle.  OBJECTIVE: To evaluate the safety and efficacy of progesterone in patients with: premenstrual syndrome, threatened abortion, preterm birth, dysfunctional uterine bleeding, mastalgia and hormone therapy in menopause.  MATERIAL AND METHODS:  Systematic review of scientific evidence about different indications of progesterone.  RESULTS: We found 92 articles from wich 41 were selected for review.  CONCLUSIONS: The clinical evidence evaluated on different indications of progesterone demonstrates advantages in efficacy and safety in different regimens.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[progesterona]]></kwd>
<kwd lng="es"><![CDATA[síndrome premenstrual]]></kwd>
<kwd lng="es"><![CDATA[amenaza de aborto]]></kwd>
<kwd lng="es"><![CDATA[amenaza de parto pretérmino]]></kwd>
<kwd lng="es"><![CDATA[mastalgia]]></kwd>
<kwd lng="es"><![CDATA[hemorragia uterina disfuncional]]></kwd>
<kwd lng="es"><![CDATA[terapia hormonal en la menopausia]]></kwd>
<kwd lng="en"><![CDATA[Progesterone]]></kwd>
<kwd lng="en"><![CDATA[Premenstrual syndrome]]></kwd>
<kwd lng="en"><![CDATA[threatened miscarriage]]></kwd>
<kwd lng="en"><![CDATA[Preterm birth]]></kwd>
<kwd lng="en"><![CDATA[Mastalgia]]></kwd>
<kwd lng="en"><![CDATA[Dysfunctional uterine bleeding]]></kwd>
<kwd lng="en"><![CDATA[hormone therapy in menopause]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Asmakh]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reproductive functions of progesterone]]></article-title>
<source><![CDATA[Middle East Fertility Society]]></source>
<year>2007</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>147-52</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orizaba-Chávez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Albo-Jasso]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ocharán-Hernández]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacocinética de la progesterona]]></article-title>
<source><![CDATA[Rev Hosp Jua Mex]]></source>
<year>2013</year>
<volume>80</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>59-66</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wieser]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progesterone increases the number of Langerhans cells in human vaginal epithelium]]></article-title>
<source><![CDATA[Fertility and Sterility]]></source>
<year>2001</year>
<volume>75</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1234-5</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marx]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wentz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[MacKay]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of progesterone on iNOS, COX-2, and collagen expression in the cervix]]></article-title>
<source><![CDATA[Journal of Histochemistry &amp; Cytochemistry]]></source>
<year>2006</year>
<volume>54</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>623-39</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bargallo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Licata]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vascular effects of progesterone Role of celular calcium regulation]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2001</year>
<volume>37</volume>
<page-range>142-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Szmuilowiez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Adler]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationship between Aldosterone and Progesterone in the human menstrual cycle]]></article-title>
<source><![CDATA[The Journal of Clinical Endocrinology &amp; Metabolism]]></source>
<year>2006</year>
<volume>91</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>3981-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Subhash]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Shashi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and treatment of premenstrual dysphoric disorder]]></article-title>
<source><![CDATA[American Academy of Family Physicians]]></source>
<year>2002</year>
<volume>66</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1239-48</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Lethaby]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mol]]></surname>
<given-names><![CDATA[BWJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progesterone for premenstrual syndrome]]></article-title>
<source><![CDATA[Cochrane Database System Rev]]></source>
<year>2009</year>
<volume>2</volume>
<page-range>CD003415</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magill]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome Progesterone Study Group]]></article-title>
<source><![CDATA[Br J Gen Pract]]></source>
<year>1995</year>
<volume>45</volume>
<numero>400</numero>
<issue>400</issue>
<page-range>589-93</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vanselow]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Dennerstein]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Greenwood]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of progesterone and its 5 alpha and 5 beta metabolites on symptoms of premenstrual syndrome according to route of administration]]></article-title>
<source><![CDATA[J Psychosom Obstet Gynaecol]]></source>
<year>1996</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>29-38</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paragiano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bulleti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pace]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy]]></article-title>
<source><![CDATA[Ann N Y Acad Sci]]></source>
<year>2004</year>
<volume>1034</volume>
<page-range>200-10</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wahabi]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Abed Althagafi]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
<name>
<surname><![CDATA[Elawad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progestogen for treating threatened miscarriage]]></article-title>
<source><![CDATA[Cochrane Database System Rev]]></source>
<year>2007</year>
<volume>3</volume>
<page-range>CD005943</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haas]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Ramsey]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progestogen for preventing miscarriage]]></article-title>
<source><![CDATA[Cochrane Database System Rev]]></source>
<year>2008</year>
<volume>2</volume>
<page-range>CD003511</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haas]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Ramsey]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progestogen for preventing miscarriage]]></article-title>
<source><![CDATA[Cochrane Database System Rev]]></source>
<year>2013</year>
<volume>10</volume>
<page-range>CD003511</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conde-Agudelo]]></surname>
</name>
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolaides]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaginal progesterone vs cervical cerclaje for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison metaanalysis]]></article-title>
<source><![CDATA[Am J Obstet Ginecol]]></source>
<year>2013</year>
<volume>208</volume>
<page-range>42.e1-18</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Di Renzo]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Cabero Roura]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Facchinetti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for the management of spontaneous preterm labor identification of spontaneous preterm labor, diagnosis of preterm premature rupture of membranes, and preventive tools for preterm birth]]></article-title>
<source><![CDATA[J Matern-Fetal Neo M]]></source>
<year>2011</year>
<volume>24</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>659-67</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roelens]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Robertfroid]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmadzai]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Prevention of preterm birth in women at risk: select topics-Abstract. Good Clinical Practice (GPC)]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Brussels ]]></publisher-loc>
<publisher-name><![CDATA[Belgian Health Care Knowledge Centre (KCE)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez-Rodríguez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Bello de Ita]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Parto pretérmino. Guía de práctica clínica]]></source>
<year>2015</year>
<page-range>250-85</page-range><publisher-name><![CDATA[COMEGO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="">
<collab>National Institute for Health and Care Excellence</collab>
<source><![CDATA[Preterm labour and birth. NICE Guidelines]]></source>
<year>2015</year>
<page-range>1-25</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dodd]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Flenady]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Cincotta]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Crowther]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prenatal administration of progesterone for preventing preterm birth]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2006</year>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Bittar]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[MHB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk A randomized placebo-controlled double-blind study]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2003</year>
<volume>188</volume>
<page-range>419-24</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Celik]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Parra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progesterone and the risk of preterm birth among women with a short cérvix]]></article-title>
<source><![CDATA[NEJM]]></source>
<year>2007</year>
<volume>357</volume>
<page-range>462-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez de Tejada]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Karolinski]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ocampo]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P) randomised double-blind pacebo-controlled trial]]></article-title>
<source><![CDATA[BJOG]]></source>
<year>2015</year>
<volume>122</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>80-91</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="book">
<collab>American College of Obstetricians and Gynecologists</collab>
<source><![CDATA[Use of progesterone to reduce preterm birth. Committee Opinion No. 419.]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Washington, DC ]]></publisher-loc>
<publisher-name><![CDATA[American College of Obstetricians and Gynecologists]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McNahara]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chalmers]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[STOPPIT Baby follow-up -Study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2015</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Norman]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Marlow]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Messow]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicenter, randomized, double-blind trial]]></article-title>
<source><![CDATA[The lancet]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosolowichi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Saettller]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Szuck]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mastalgia]]></article-title>
<source><![CDATA[Clinical Practice Guideline]]></source>
<year>2006</year>
<numero>170</numero>
<issue>170</issue>
<page-range>49-57</page-range><publisher-name><![CDATA[SOGC]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nappi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Affinito]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[DiCarlo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Esposito]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Montemagn]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease]]></article-title>
<source><![CDATA[J Endocrinol Invest]]></source>
<year>1992</year>
<volume>15</volume>
<page-range>801-6</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Euhus]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Uyehara]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influence of parental progesterone's on the prevalence and severity of mastalgia in pre-menopausal women a multi-institutional cross-sectional study]]></article-title>
<source><![CDATA[J Am Coll Surg]]></source>
<year>1997</year>
<volume>84</volume>
<page-range>596-604</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mainero-Ratchelous]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
<name>
<surname><![CDATA[López-Valle]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Iturralde-Rosas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Mastalgia. Guía de Práctica Clínica]]></source>
<year>2015</year>
<page-range>101-15</page-range><publisher-name><![CDATA[COMEGO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stanczyk]]></surname>
<given-names><![CDATA[FZ]]></given-names>
</name>
<name>
<surname><![CDATA[Hapgood]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Winer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mishell]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progestogens used in postmenopausal hormone therapy differences in their pharmacological properties, intracellular actions and clinical effects]]></article-title>
<source><![CDATA[Endocrine Rev]]></source>
<year>2013</year>
<volume>34</volume>
<page-range>171-208</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miles]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Paulson]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lobo]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes a comparative study]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>1994</year>
<volume>62</volume>
<page-range>485-90</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[L'Hermite]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Simoncine]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Fuller]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Could transdermal estradiol + progesterone be a safer postmenopausal HRT A review]]></article-title>
<source><![CDATA[Maturitas]]></source>
<year>2008</year>
<volume>60</volume>
<page-range>185-201</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khul]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacology of Progestogens]]></article-title>
<source><![CDATA[J Reproduktionsmed Endokrinol]]></source>
<year>2011</year>
<volume>8</volume>
<numero>Special Issue 1</numero>
<issue>Special Issue 1</issue>
<page-range>157-76</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="">
<source><![CDATA[Vademecum PR]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="book">
<collab>The Royal Australian and New Zealand College of Obstetricians and Gynecologist</collab>
<source><![CDATA[Menopausal Hormone Therapy Advice]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Australia ]]></publisher-loc>
<publisher-name><![CDATA[RANZCOG]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The 2012 Hormone Therapy Position Statement of the North American Menopause Society]]></article-title>
<source><![CDATA[Menopause]]></source>
<year>2012</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>257-71</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<collab>The Society of Obstetricians and gynaecologist of Canada. (SOGC)</collab>
<article-title xml:lang=""><![CDATA[Abnormal uterine bleeding in pre-menopausal women]]></article-title>
<source><![CDATA[FIGO]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Derman]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Rehnstrom]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Neuwirth]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The long term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas]]></article-title>
<source><![CDATA[Obstet Gynecol]]></source>
<year>1991</year>
<volume>77</volume>
<page-range>591-4</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alanís-Fuentes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zacarías-Castillo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sangrado uterino anormal (y el endocrinólogo)]]></article-title>
<source><![CDATA[Endocrinol Nutr]]></source>
<year>2005</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-46</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stacy]]></surname>
<given-names><![CDATA[R.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Nelson]]></surname>
<given-names><![CDATA[A.L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: a pilot sudy]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2013</year>
<volume>208</volume>
<page-range>499.e1-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
